Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:41 pm Purchase |
2023-12-31 | 13G | CARGO Therapeutics, Inc. Common Stock CRGX |
Perceptive Advisors LLC | 3,436,600 8.300% |
190,432 (+5.87%) |
Filing History |
| 2024-02-14 4:40 pm Purchase |
2023-12-31 | 13G | Leap Therapeutics, Inc. LPTX |
Perceptive Advisors LLC | 1,068,497 4.000% |
1,068,497 (New Position) |
Filing History |
| 2024-02-14 4:39 pm Purchase |
2023-12-31 | 13D | MeiraGTx Holdings plc MGTX |
Perceptive Advisors LLC | 11,442,562 18.000% |
35,999 (+0.32%) |
Filing History |
| 2024-02-14 4:38 pm Purchase |
2023-12-31 | 13G | enVVeno Medical Corporation NVNO |
Perceptive Advisors LLC | 1,394,716 9.900% |
457,201 (+48.77%) |
Filing History |
| 2024-02-14 4:38 pm Purchase |
2023-12-31 | 13G | Amicus Therapeutics, Inc. FOLD |
Perceptive Advisors LLC | 28,057,456 9.600% |
414,539 (+1.50%) |
Filing History |
| 2024-02-14 4:36 pm Unchanged |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Perceptive Advisors LLC | 3,007,858 13.600% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:36 pm Sale |
2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
Perceptive Advisors LLC | 1,869,125 2.800% |
-4,219,208 (-69.30%) |
Filing History |
| 2024-02-14 4:34 pm Purchase |
2023-12-31 | 13G | Celcuity Inc. CELC |
Perceptive Advisors LLC | 1,481,300 6.100% |
40,000 (+2.78%) |
Filing History |
| 2024-02-14 4:32 pm Sale |
2023-12-31 | 13G | Veru Inc. VERU |
Perceptive Advisors LLC | 5,584,699 3.800% |
-2,273,312 (-28.93%) |
Filing History |
| 2024-02-14 4:31 pm Purchase |
2023-12-31 | 13G | Evolus, Inc. EOLS |
Perceptive Advisors LLC | 3,963,424 6.900% |
876,820 (+28.41%) |
Filing History |
| 2024-02-14 4:29 pm Unchanged |
2024-02-14 | 13D | Lyra Therapeutics, Inc. LYRA |
Perceptive Advisors LLC | 255,151 24.300% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:29 pm Purchase |
2023-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
Perceptive Advisors LLC | 11,979,415 4.700% |
2,007,635 (+20.13%) |
Filing History |
| 2024-02-14 4:27 pm Sale |
2023-12-31 | 13G | Verona Pharma plc VRNA |
Perceptive Advisors LLC | 3,866,214 4.800% |
-596,452 (-13.37%) |
Filing History |
| 2024-02-14 4:27 pm Unchanged |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Perceptive Advisors LLC | 2,606,679 7.200% |
0 (Unchanged) |
Filing History |
| 2024-02-12 4:16 pm Purchase |
2024-02-01 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
Perceptive Advisors LLC | 3,260,013 5.500% |
3,260,013 (New Position) |
Filing History |
| 2024-02-09 7:51 pm Purchase |
2024-01-30 | 13D | Trinity Biotech plc TRIB |
Perceptive Advisors LLC | 11,200,000 26.800% |
11,200,000 (New Position) |
Filing History |
| 2024-02-05 4:14 pm Purchase |
2024-02-01 | 13D | Astria Therapeutics, Inc. ATXS |
Perceptive Advisors LLC | 6,485,420 11.900% |
2,857,727 (+78.78%) |
Filing History |
| 2024-01-29 4:53 pm Purchase |
2024-01-18 | 13G | Viridian Therapeutics, Inc. VRDN |
Perceptive Advisors LLC | 4,022,066 6.700% |
4,022,066 (New Position) |
Filing History |
| 2024-01-19 4:37 pm Purchase |
2024-01-09 | 13G | Fusion Pharmaceuticals Inc. FUSN |
Perceptive Advisors LLC | 4,737,194 6.500% |
4,737,194 (New Position) |
Filing History |
| 2024-01-12 5:11 pm Purchase |
2024-01-11 | 13D | Solid Biosciences Inc. SLDB |
Perceptive Advisors LLC | 6,925,028 18.600% |
3,423,763 (+97.79%) |
Filing History |